229 results on '"Loblaw, D. Andrew"'
Search Results
2. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
3. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline
4. Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials
5. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
6. A 2011 Updated Systematic Review and Clinical Practice Guideline for the Management of Malignant Extradural Spinal Cord Compression
7. Population Based Study of Long-Term Rates of Surgery for Urinary Incontinence After Radical Prostatectomy for Prostate Cancer
8. Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer
9. Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer: Late Toxicity
10. Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy
11. Health-Related Quality of Life After Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Prostate Cancer
12. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond
13. Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities
14. Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Men With Intermediate-Risk Prostate Cancer: Analysis of Short- and Medium-Term Toxicity and Quality of Life
15. Increasing Hospital Admission Rates for Urological Complications After Transrectal Ultrasound Guided Prostate Biopsy
16. Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse
17. Prospective Study Evaluating Postoperative Radiotherapy Plus 2-Year Androgen Suppression for Post–Radical Prostatectomy Patients With Pathologic T3 Disease and/or Positive Surgical Margins
18. Do ongoing lifestyle disruptions differ across cancer types after the conclusion of cancer treatment?
19. Pain flare in patients with bone metastases after palliative radiotherapy—a nested randomized control trial
20. Does tumor status influence cancer patients’ satisfaction with the doctor-patient interaction?
21. Measurement Invariance of the Illness Intrusiveness Ratings Scaleʼs Three-Factor Structure in Men and Women With Cancer
22. Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
23. Prospective Evaluation of the Concordance between Radiation Therapists and Radiation Oncologists on Daily Verification Films
24. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer
25. CONTEXT MODERATES ILLNESS-INDUCED LIFESTYLE DISRUPTIONS ACROSS LIFE DOMAINS: A TEST OF THE ILLNESS INTRUSIVENESS THEORETICAL FRAMEWORK IN SIX COMMON CANCERS
26. Systematic Review of the Diagnosis and Management of Malignant Extradural Spine Cord Compression: The Cancer Care Ontario Practice Guidelines Initiativeʼs Neuro-Oncology Disease Site Group
27. American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer
28. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline
29. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
30. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
31. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline
32. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion
33. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Summary
34. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update
35. Opportunity lost and found: Any easy way to improve outcomes for prostate cancer patients in the postoperative setting?
36. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer
37. Cautionary tale of active surveillance in intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook experience.
38. Comparison of active surveillance with other treatment options for low-risk prostate cancer.
39. Quality of life (QOL) and acute toxicities of a pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT).
40. Dose escalation of five-fraction SABR for prostate cancer: Biochemical outcome and toxicity comparison of two prospective trials.
41. PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time.
42. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline Summary
43. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
44. Pilot study of focal salvage high-dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT).
45. Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer
46. How does stereotactic body radiotherapy compare to standard external beam radiotherapy or low-dose rate brachytherapy for low-risk prostate cancer?
47. Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists
48. Wait times in prostate cancer diagnosis and radiation treatment
49. A prospective study on pain score with transperineal prostatic gold seed fiducial implantation under local anesthetic alone
50. Capsaicin may slow PSA doubling time: case report and literature review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.